Quick Answer
KALA BIO, Inc. reported R&D Expense of $18.35 million for fiscal year 2020.
KALA BIO, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2020 | $18.35M | -32.7% |
| 2019 | $27.27M | -6.9% |
| 2018 | $29.29M | +1.0% |
| 2017 | $29.01M | +15.9% |
| 2016 | $25.03M | +119.9% |
| 2015 | $11.38M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.13M | +18.6% | -1.7% |
| June 30, 2025 | $6.23M | +17.2% | +2.9% |
| March 31, 2025 | $6.05M | -4.7% | +17.2% |
| September 30, 2024 | $5.17M | -6.9% | -2.8% |
| June 30, 2024 | $5.32M | +24.3% | -16.3% |
| March 31, 2024 | $6.35M | +57.4% | +14.4% |
| September 30, 2023 | $5.55M | +3.0% | +29.8% |
| June 30, 2023 | $4.28M | -4.4% | +6.0% |
- KALA BIO, Inc. showed a decrease of -32.7% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2020 period, KALA BIO, Inc.’s r&d expense has grown by 61.2% (from $11.38 million to $18.35 million).
- The most recent figure is from KALA BIO, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on February 25, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: